A116 LOSS OF RESPONSE TO VEDOLIZUMAB MAINTENANCE THERAPY IN CROHN`S DISEASE

BACKGROUND: Vedolizumab is a gut-specific alpha-4-beta-7 integrin antagonist that has demonstrated efficacy in induction and maintenance of clinical response and remission in Crohn’s disease randomized controlled trials. AIMS: To evaluate the long-term maintenance of response achieved with vedolizum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Ma, C, Kotze, P, Almutairdi, A, Al-Darmaki, A, Devlin, S, Kaplan, G G, Seow, C, Novak, K L, Lu, C, Ferraz, J, Stewart, M J, Buresi, M c, Mathivanan, M, Heatherington, J, Martin, M, Panaccione, R
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Paper Sessions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508321/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.116
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados